This Article Full Text Full Text (PDF) Other Versions of this Article: AAC.01263-06v1 51/3/877    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Dodds Ashley, E. S. Articles by Perfect, J. R. Search for Related Content PubMed PubMed Citation Articles by Dodds Ashley, E. S. Articles by Perfect, J. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2007, p. 877-880, Vol. 51, No. 3
0066-4804/07/$08.00+0     doi:10.1128/AAC.01263-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Comparative Pharmacokinetics of Voriconazole Administered Orally as either Crushed or Whole Tablets

Duke University Medical Center, Durham, North Carolina,¹ Pfizer Inc., New York, New York²

Received 9 October 2006/ Accepted 27 November 2006

Voriconazole is a triazole antifungal agent used to treat serious, invasive fungal infections including aspergillosis and candidemia. Limitations with existing formulations of voriconazole including restricted utility in patients with renal dysfunction (intravenous preparation) and the unavailability of an oral suspension in some countries make the administration of crushed tablets desirable in many clinical scenarios. However, concerns that this approach may alter the systemic absorption of voriconazole exist. Therefore, an open-label, randomized, two-way crossover comparative pharmacokinetic (PK) study using healthy volunteers was performed to compare these methods of tablet administration. In a random sequence, subjects received voriconazole tablets either crushed or whole. The voriconazole dose was 400 mg every 12 h for 1 day orally followed by 200 mg every 12 h orally for 5.5 days. Study periods were separated by 7 days. PK parameters were determined by the noncompartmental method. An equivalence approach with no-effect boundaries of 80 to 125% was used to assess bioequivalence. Twenty healthy subjects (10 males; aged 20 to 43 years) were enrolled in and completed the study. The adjusted mean areas under the plasma concentration-time curve from 0 to , where equals 12 h, for the crushed and whole tablet groups were 9,793 and 11,164 ng · h/ml, respectively (ratio, 87.72; 90% confidence interval [CI], 80.97, 95.04). The ratio of the maximum concentration of drug in serum for the crushed tablet versus whole tablet arms was 94.94 (90% CI, 86.51, 104.22). The only difference noted between groups was a slightly faster time to maximum concentration of drug in serum when subjects received crushed tablets, 0.5 h versus 1.5 h (90% CI, –0.75, –0.25). Treatment-related adverse events occurred in 12 subjects receiving whole tablets and 9 subjects receiving crushed tablets; all were mild. The administration of crushed voriconazole tablets is bioequivalent to whole-tablet administration.

Published ahead of print on 4 December 2006.